CHILDREN'S HEALTH	Page 1 of 4			
	Patient Name:			
	Date of Birth:			
PHYO Bortezomib (VELCADE) EX0057-001NS Rev. 12/2022 Injection Therapy Plan				
Baseline Patient Demographic				
To be completed by the ordering provider.				
Diagnosis: kg Body Surface Area: (m <sup>2</sup> )				
NKDA - No Known Drug Allergies Allergies:				
Therapy Plan orders extend over time (several visits) including recurring treat	ment.			
Please specify the following regarding the entire course of therapy:				
	unknown			
	hin the month			
**Plans must be reviewed / re-ordered at least annually. **				
ORDERS TO BE COMPLETED FOR EACH THERAPY				
ADMIT ORDERS				
✓ Height and weight				
☑ Vital signs				
Hypotension Defined Admit				
V Nursing communication	noise as defined by the following perspectate. This information will be			
Prior to starting infusion, please determine the patient's threshold for hypoter needed in the event of an infusion reaction occurring.	ision as defined by the following parameters. This information will be			
Hypotension is defined as follows: 1 month to 1 year - systolic blood pressure (SBP) less than 70				
1 year to 11 years - systolic blood pressure (SBP) less than 70 + (2 x age in year	ears)			
11 years to 17 years - systolic blood pressure (SBP) less than 90 OR any age - systolic blood pressure (SBP) drop of more than 30% from base	line.			
Baseline systolic blood pressure (SBP) x 0.7 = value below defined as hypotension.				
NURSING ORDERS				
Please select all appropriate therapy				
IV START NURSING ORDERS				
Insert peripheral IV / Access IVAD Place PIV if needed or access IVAD if available				
Iidocaine 1% BUFFERED (J-TIP LIDOCAINE)				
0.2 mL, INTRADERMAL, PRN				
when immediate procedure needed when procedure will take about 1	1 minute D patient / family preference for procedure			
Administration Instructions: NOTE: Do not use this medication in patients anticoagulants, when accessing implanted ports or using a vein that will be neonates.				
Iidocaine - prilocaine (EMLA) cream TOPICAL, PRN				
$\Box$ when more than 60 minutes are available before procedure $\Box$ when pro	ocedure will take more than 1 hour			
☐ patient / family preference for procedure				
Administration Instructions: NOTE: In children < 3 months of age, or < 5 kg in weight, maximum application time is 1 hour.				

## CHILDREN'S HEALTH



PHYO

EX0057-001NS

## Bortezomib (VELCADE) Injection Therapy Plan

#### ORDERS TO BE COMPLETED FOR EACH THERAPY

#### NURSING ORDERS, CONTINUED

Rev. 12/2022

### ☐ lidocaine with transparent dressing 4% kit

TOPICAL, PRN

U when 20 - 30 minutes are available before procedure U when procedure will take more than 1 hour

patient / family preference for procedure

#### Heparin flush

#### heparin flush

10 - 50 units, INTRAVENOUS, PRN, IV line flush. Per protocol, heparin should not be used to flush peripheral IVs. This heparin flush should be used with all central lines including IVADs, with the exception of de-accessing the IVAD.

#### heparin flush

100 - 300 units, INTRAVENOUS, PRN, IV line flush. Per protocol, heparin should not be used to flush peripheral IVs. For use only when de-accessing IVADs.

#### Sodium chloride flush

#### Sodium chloride flush 0.9% injection

1 - 20 mL, INTRAVENOUS, PRN, IV line flush

#### Sodium chloride - preservative free 0.9% injection

1 - 30 mL, INTRAVENOUS, PRN, IV line flush

#### PRE - PROCEDURE LABS

Basic Metabolic Panel     Unit collect	INTERVAL:	Every visit
Magnesium Unit collect	INTERVAL:	Every visit
Phosphorus Unit collect	INTERVAL:	Every visit
Complete Blood Count With Differential Unit collect	INTERVAL:	Every visit
Hepatic Function Panel     Unit collect	INTERVAL:	Every visit
Gamma Glutamyl Transferase Unit collect	INTERVAL:	Every visit

#### **INTRA - PROCEDURE**

#### Physician Communication Order

Therapy to be administered on days 1, 4, 8 and 11. If an additional cycle is needed, there must be a 14 day break before the next cycle.

Bortezomib subcutaneous or intravenous				
<ul> <li>O Bortezomib subcutaneous injection 1.3 mg / m<sup>2</sup></li> <li>1.3 mg / m<sup>2</sup>, SUBCUTANEOUS, ONCE, for 1 dose</li> </ul>	INTERVAL: Every visit	DURATION: Until discontinued		
Please contact pharmacy 1 hour prior to administration so dose can be prepared.				
Dose:				
<ul> <li>Bortezomib IV ONLY injection 1.3 mg / m<sup>2</sup></li> <li>1.3 mg / m<sup>2</sup>, INTRAMUSCULAR, ONCE, for 1 dose</li> <li>Please contact pharmacy 1 hour prior to administration so dose can</li> <li>Dose:</li> </ul>	INTERVAL: Every visit be prepared.	DURATION: Until discontinued		

Page 2 of 4

Date of Birth:

Patient Name:

Key: cm = centimeter; IV = intravenous; IVAD = implantable venous access device; kg = kilogram; m<sup>2</sup> = square meters; mg = milligram; mL = milliliter; mL / hr = milliliters per hour; mOsm / L = milliosmole per liter; NKDA = no known drug allergies; pH = hydrogen ion concentration; PIV = peripheral intravenous; PRN = as neededvenous catheter; SBP = systolic blood pressure



PHYO

EX0057-001NS

## Bortezomib (VELCADE) Injection Therapy Plan

#### ORDERS TO BE COMPLETED FOR EACH THERAPY

## **INTRA - PROCEDURE, CONTINUED**

Rev. 12/2022

#### Therapy Appointment Request

#### Please select department for the therapy appointment request:

Expires in 365 days

Dallas Special Procedures Plano Infusion Center Dallas Allergy Dallas Transplant Dallas Neurology Bortezomib dosing schedule is twice weekly for two weeks. At least 3 days should elapse between consecutive doses of bortezomib.

EMERGENCY MEDICATIONS

## ✓ Nursing communication

1. Hives or cutaneous reaction only - no other system involvement PATIENT IS HAVING A DRUG REACTION:

- a. Stop the infusion
- b. Give diphenhydramine as ordered
- c. Check heart rate, respiratory rate and blood pressure every 5 minutes until further orders from provider.
- d. Connect patient to monitor (cardiac / apnea, blood pressure and oxygen saturation) if not already on one
- e. Notify provider for further orders
- 2. Hives or cutaneous reaction plus one other system, i.e. abdominal cramping, vomiting, hypotension, altered mental status, respiratory distress, mouth / tongue swelling

## PATIENT IS HAVING ANAPHYLAXIS:

- a. Stop the infusion
- b. Call code do not wait to give epinephrine
- c. Give epinephrine as ordered
- d. Notify provider
- e. Check heart rate, respiratory rate and blood pressure every 5 minutes until the code team arrives.
- f. Connect patient to monitor (cardiac / apnea, blood pressure and oxygen saturation), if not already on one.
- g. Give diphenhydramine once as needed for hives
- h. May repeat epinephrine every 5 minutes x 2 doses for persistent hypotension and respiratory distress with desaturation until code team arrives.
- i. May give albuterol as ordered for wheezing with oxygen saturation stable while waiting for code team, continue to monitor oxygen saturation.

#### EPINEPHrine Injection Orderable For Therapy Plan (AMPULE / EPI - PEN JR. / EPI - PEN) 0.01 mg / kg

0.01 mg / kg, INTRAMUSCULAR, EVERY 5 MINUTES PRN, for anaphylaxis and may be repeated for persistent hypotension and respiratory distress with desaturation until the code team arrives, for 3 doses

Use caution with PIV administration. This solution has a pH < 5, or a pH > 9, or an osmolality > 600 mOsm / L.

Dose: -

# 

# Cardio / Respiratory Monitoring Rationale for Monitoring: High risk patient (please specify risk)

- Clinically significant cardiac anomalies or dysrhythmias
- □ Recent acute life-threatening event
- □ Unexplained or acutely abnormal vital signs
- □ Artificial airway (stent, tracheostomy, oral airway)
- □ Acute, fluctuating or consistent oxygen requirements

Monitor Parameters (select all that apply): 🔲 Heart rate 🛛 🛛 Oxygen saturation 🔹 Respiratory rate

Telemetry Required: Ves No

# diphenhydrAMINE injection

1 mg / kg, INTRAVENOUS, ONCE PRN, for hives or cutaneous reaction, for 1 dose. Maximum dose = 50 mg per dose, 300 mg per day. Dose:

# Albuterol for aerosol

0.25 mg / kg., INHALATION ONCE PRN, for wheezing, but oxygen saturations stable while waiting for code team, continue to monitor oxygen saturation for 1 dose

Dose:

Patient Name:

# CHILDREN'S HEALTH



PHYO EX0057-001NS Rev. 12/2022

# Bortezomib (VELCADE) Injection Therapy Plan

#### ORDERS TO BE COMPLETED FOR EACH THERAPY

## **POST - PROCEDURE**

## ☐ Vital signs monitor patient for 15 minutes post injection.

Monitor patient for 15 minutes post injection

#### □ POST-PROCEDURE

Flush PIV or IVAD with 20 mL 0.9% sodium chloride (250 mL bag) at the completion of the infusion. Flush IVAD with saline and heparin flush per protocol prior to de-accessing IVAD. Discontinue prior to discharge on the last day of infusion.

(circle one): MD DO

Credentials

#### Sodium chloride 0.9% infusion

INTRAVENOUS at 0 - 25 mL / hr. ONCE, for 1 dose.

Dose: \_\_\_\_

Signature of Provider

Printed Name of Provider

. .....

Patient Name: \_

Date of Birth:

Date

Time

Page 4 of 4